Antidiabetic drugs

Abstract Over recent years, there has been a rapid expansion of different classes of antihyperglycaemic drugs with diverse toxicological profiles. Insulin and sulfonylurea overdose can cause significant hypoglycaemia, which is reversed by administration of intravenous glucose 10–20%, aiming to achie...

Full description

Saved in:
Bibliographic Details
Published inMedicine (Abingdon. 1995, UK ed.) Vol. 44; no. 3; pp. 138 - 140
Main Author Waring, W Stephen
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.03.2016
Subjects
Acarbose
antidiabetic
DPP-IV inhibitor
GLP-1
insulin
Internal Medicine
meglitinides
metformin
overdose
sulfonylureas
thiazolidinediones
overdose
thiazolidinediones
Acarbose
GLP-1
insulin
meglitinides
sulfonylureas
metformin
antidiabetic
DPP-IV inhibitor
Online AccessGet full text

Cover

More Information
Summary:Abstract Over recent years, there has been a rapid expansion of different classes of antihyperglycaemic drugs with diverse toxicological profiles. Insulin and sulfonylurea overdose can cause significant hypoglycaemia, which is reversed by administration of intravenous glucose 10–20%, aiming to achieve a target plasma glucose concentration of ≥4 mmol/litre. However, glucose alone is a potent stimulus for additional insulin release in sulfonylurea-poisoned patients and can result in recurrent and prolonged rebound hypoglycaemia. Octreotide inhibits the secretion of insulin from the pancreas and, when used in sulfonylurea poisoning, is associated with a marked reduction in hypoglycaemic episodes and glucose requirements.
ISSN:1357-3039
1878-9390
DOI:10.1016/j.mpmed.2015.12.011